Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:IPHYF NASDAQ:NKTR NASDAQ:PROK NASDAQ:RLAY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPHYFInnate Pharma$2.06$1.68$1.31▼$2.06$172.65M0.51N/AN/ANKTRNektar Therapeutics$48.57+9.6%$26.63$6.45▼$48.85$843.09M1.06908,646 shs1.88 million shsPROKProKidney$2.21+2.3%$2.68$0.46▼$7.13$635.65M1.741.58 million shs1.53 million shsRLAYRelay Therapeutics$4.07+0.2%$3.61$1.77▼$10.13$699.99M1.61.21 million shs834,667 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPHYFInnate Pharma0.00%0.00%+57.21%+42.03%-10.46%NKTRNektar Therapeutics+9.56%+67.02%+110.62%+408.59%+174.41%PROKProKidney+2.31%-3.91%-14.47%+136.39%-7.53%RLAYRelay Therapeutics+0.25%+11.20%+26.40%+21.86%-57.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPHYFInnate Pharma$2.06$1.68$1.31▼$2.06$172.65M0.51N/AN/ANKTRNektar Therapeutics$48.57+9.6%$26.63$6.45▼$48.85$843.09M1.06908,646 shs1.88 million shsPROKProKidney$2.21+2.3%$2.68$0.46▼$7.13$635.65M1.741.58 million shs1.53 million shsRLAYRelay Therapeutics$4.07+0.2%$3.61$1.77▼$10.13$699.99M1.61.21 million shs834,667 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPHYFInnate Pharma0.00%0.00%+57.21%+42.03%-10.46%NKTRNektar Therapeutics+9.56%+67.02%+110.62%+408.59%+174.41%PROKProKidney+2.31%-3.91%-14.47%+136.39%-7.53%RLAYRelay Therapeutics+0.25%+11.20%+26.40%+21.86%-57.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIPHYFInnate Pharma 0.00N/AN/AN/ANKTRNektar Therapeutics 2.86Moderate Buy$88.3381.87% UpsidePROKProKidney 2.33Hold$6.25182.81% UpsideRLAYRelay Therapeutics 3.00Buy$16.50305.41% UpsideCurrent Analyst Ratings BreakdownLatest IPHYF, RLAY, NKTR, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025RLAYRelay TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.008/26/2025RLAYRelay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $14.008/18/2025PROKProKidneyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/8/2025RLAYRelay TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetStrong-Buy$29.00 ➝ $19.007/15/2025PROKProKidneyUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$4.00 ➝ $8.007/14/2025PROKProKidneyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.00 ➝ $7.007/9/2025PROKProKidneyCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.00 ➝ $9.007/8/2025NKTRNektar TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $85.006/30/2025PROKProKidneyBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.00 ➝ $1.006/24/2025NKTRNektar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $100.006/24/2025NKTRNektar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$120.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIPHYFInnate Pharma$21.77M7.93N/AN/A$0.11 per share18.72NKTRNektar Therapeutics$98.43M9.39N/AN/A$4.94 per share9.83PROKProKidney$80K8,129.49N/AN/A($3.41) per share-0.65RLAYRelay Therapeutics$8.36M83.99N/AN/A$4.65 per share0.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIPHYFInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)NKTRNektar Therapeutics-$118.96M-$8.80N/AN/AN/A-163.17%-631.43%-58.21%11/6/2025 (Estimated)PROKProKidney-$61.19M-$0.57N/AN/AN/AN/AN/A-17.11%11/11/2025 (Estimated)RLAYRelay Therapeutics-$337.71M-$1.95N/AN/AN/AN/A-41.49%-37.43%11/5/2025 (Estimated)Latest IPHYF, RLAY, NKTR, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025PROKProKidney-$0.14-$0.13+$0.01-$0.13N/A$0.22 million8/7/2025Q2 2025NKTRNektar Therapeutics-$3.13-$2.95+$0.18-$2.95$9.42 million$11.18 million8/7/2025Q2 2025RLAYRelay Therapeutics-$0.49-$0.41+$0.08-$0.41$0.07 million$0.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIPHYFInnate PharmaN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIPHYFInnate PharmaN/A2.602.60NKTRNektar TherapeuticsN/A2.612.61PROKProKidneyN/A11.4811.48RLAYRelay TherapeuticsN/A20.9220.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIPHYFInnate PharmaN/ANKTRNektar Therapeutics75.88%PROKProKidney51.59%RLAYRelay Therapeutics96.98%Insider OwnershipCompanyInsider OwnershipIPHYFInnate Pharma31.89%NKTRNektar Therapeutics3.71%PROKProKidney41.49%RLAYRelay Therapeutics4.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIPHYFInnate Pharma17983.83 million57.10 millionNot OptionableNKTRNektar Therapeutics22019.02 million18.31 millionOptionablePROKProKidney3294.28 million172.18 millionOptionableRLAYRelay Therapeutics330172.41 million164.96 millionOptionableIPHYF, RLAY, NKTR, and PROK HeadlinesRecent News About These CompaniesTrexquant Investment LP Lowers Holdings in Relay Therapeutics, Inc. $RLAYSeptember 9 at 3:33 AM | marketbeat.comRelay Therapeutics (RLAY) Receives a Buy from GuggenheimSeptember 9 at 2:06 AM | theglobeandmail.comInvesting in Oncology: 3 Cancer Stocks With Promising PipelinesSeptember 8 at 10:45 AM | zacks.comParkman Healthcare Partners LLC Sells 312,496 Shares of Relay Therapeutics, Inc. $RLAYSeptember 8 at 7:45 AM | marketbeat.comInvesco Ltd. Has $484,000 Position in Relay Therapeutics, Inc. $RLAYSeptember 8 at 3:12 AM | marketbeat.comGuggenheim Gives Buy Rating to Relay Therapeutics (RLAY)September 8 at 2:51 AM | insidermonkey.comOMERS ADMINISTRATION Corp Makes New Investment in Relay Therapeutics, Inc. $RLAYSeptember 7 at 4:12 AM | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Research Coverage Started at GuggenheimSeptember 7 at 2:47 AM | americanbankingnews.comGuggenheim Initiates Coverage on Relay Therapeutics (NASDAQ:RLAY)September 6, 2025 | marketbeat.comWalleye Capital LLC Sells 825,589 Shares of Relay Therapeutics, Inc. $RLAYSeptember 6, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Trading Up 7.6% - What's Next?September 5, 2025 | marketbeat.comGuggenheim assumes Relay with Buy, names best ideaSeptember 4, 2025 | msn.comNuveen LLC Purchases Shares of 320,395 Relay Therapeutics, Inc. $RLAYSeptember 4, 2025 | marketbeat.comRelay Therapeutics assumed with a Buy at GuggenheimSeptember 3, 2025 | msn.comWill Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?August 30, 2025 | finance.yahoo.comHC Wainwright Issues Positive Outlook for RLAY EarningsAugust 30, 2025 | marketbeat.comCW Advisors LLC Makes New Investment in Relay Therapeutics, Inc. $RLAYAugust 30, 2025 | marketbeat.comVanguard Group Inc. Reduces Stock Position in Relay Therapeutics, Inc. $RLAYAugust 30, 2025 | marketbeat.comEquities Analysts Offer Predictions for RLAY Q3 EarningsAugust 30, 2025 | americanbankingnews.comBrokers Offer Predictions for RLAY FY2026 EarningsAugust 29, 2025 | marketbeat.comRelay Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberAugust 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPHYF, RLAY, NKTR, and PROK Company DescriptionsInnate Pharma OTCMKTS:IPHYF$2.06 0.00 (0.00%) As of 09/8/2025Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Nektar Therapeutics NASDAQ:NKTR$48.57 +4.24 (+9.56%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$48.48 -0.09 (-0.18%) As of 09/9/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.ProKidney NASDAQ:PROK$2.21 +0.05 (+2.31%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$2.19 -0.02 (-0.68%) As of 09/9/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Relay Therapeutics NASDAQ:RLAY$4.07 +0.01 (+0.25%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$4.10 +0.03 (+0.74%) As of 09/9/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
